We have previously reported that anti-MT monoclonal therapeutic treatment can ameliorate the destructive inflammation of IBD, leading us to evaluate this course of treatment in another model of autoimmune inflammation. The gene discussed is MCAT; the disease is inflammatory bowel disease.